Εx-vivo effect of dexamethasone on cytokine production from whole blood of septic patients: Correlation with disease severity

Cytokine

Volumn 49, Issue 1, 2010, Pages 89-94

  Giamarellos Bourboulis, Evangelos J ^a   Dimopoulou, Ioanna ^a   Kotanidou, Anastasia ^a   Livaditi, Olga ^a   Pelekanou, Aimilia ^a   Tsagarakis, Stylianos ^b   Armaganidis, Apostolos ^a   Orfanos, Stylianos E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Polyclinic of Athens ^*  (Greece)

Author keywords

Dexamethasone; Interleukin 1beta; Sepsis; sTREM 1; Survival

Indexed keywords

CYTOKINE; DEXAMETHASONE SODIUM PHOSPHATE; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; INCUBATION TIME; MALE; PRIORITY JOURNAL; SEPSIS; SUPERNATANT; TREATMENT OUTCOME; AGED; BLOOD; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SURVIVAL;

ADULT; AGED; CYTOKINES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL;

EID: 71949084153     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.08.016     Document Type: Article

References (24)

1. Rittisch D., Flierl M.A., and Ward P.A. Harmful molecular mechanisms in sepsis. Nat Immunol 8 (2008) 776-786
2. Wang H., and Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 26 (2008) 711-715
3. Wang X., Nelin L.D., Kuhlman J.R., Meng X., Welty S.E., and Liu Y. The role of MAP kinase phosphatase-1 in the protective mechanism of dexamethasone against endotoxemia. Life Sci 83 (2008) 671-680
4. Annane D., Sébille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
5. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 (2008) 111-124
6. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30 (2004) 536-555
7. Levy M., Fink Μ.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31 (2003) 1250-1256
8. Vincent J.L. Ventilator-associated pneumonia. J Hosp Infect 57 (2004) 272-280
9. Pugin J., Auckenthaler R., Mili N., et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 143 (1991) 1121-1129
10. Calandra T., and Cohen J. The International Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med 33 (2005) 1639-1648
11. Ebrecht M., Buske-Kirschbaum A., Hellehamer D., et al. Tissue specificity of glucocorticoid sensitivity in healthy adults. J Clin Endocrinol Metab 85 (2000) 3733-3739
12. Gratsias Y., Moutsatsou P., Chrysanthopoulou G., et al. Diurnal changes in glucocorticoid sensitivity in human peripheral blood samples. Steroids 65 (2000) 851-856
13. Nakade S., Ohno T., Kitagawa J., et al. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 63 (2008) 75-83
14. Hong Y., Mager D.E., Blum R.A., and Jusko W.J. Population pharmacokinetic/pharmacodymamic modelling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodymanic variability. Pharm Res 24 (2007) 1088-1097
15. Tóth G.G., Kloosterman C., Uges D.R., and Jonkman M.F. Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit 21 (1999) 532-535
16. Cook E.B., Stahl J.L., Lowe L., et al. Simultaneous measurement of six cytokines in a sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods 254 (2001) 109-118
17. Chen R., Lowe L., Wilson J.D., et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem 45 (1999) 1693-1694
18. Vincent J.L., Sun Q., and Dubois M.J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34 (2003) 1084-1093
19. Marik P.E., Pastores S.M., Annane D., et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 36 (2008) 1937-1949
20. Kox W.J., Bone R.C., Krausch D., et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. Arch Intern Med 157 (1997) 389-393
21. Hermann C., von Aulock S., Dehus O., et al. Endogenous cortisol determines the cicardian rythm of lipopolysaccharide-but not lipoteichoic acid-inducible cytokine release. Eur J Immunol 36 (2006) 371-379
22. Drenth J.P.H., and van Der Meer J.W.M. The inflammasome-a linebacker of innate defense. N Engl J Med 355 (2006) 730-732
23. Tesarz A.S., and Cerwenka A. The TREM-1/DAP12 pathway. Immunol Lett 116 (2008) 111-116
24. Gibot S., Kolopp Sarda M.N., Béné M.C., et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 11 (2004) 1419-1426